Amgen Receives Positive Opinion Expanding Use Of XGEVA(R) (denosumab) To Cover Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma In Europe

Application Based on Data From Largest International Multiple Myeloma Trial for the Prevention of Skeletal-Related Events Ever Conducted THOUSAND OAKS, Calif., Feb. 23, 2018 -- (Healthcare Sales & Marketing Network) -- Amgen (NASDAQ: AMGN) today announ... Biopharmaceuticals, Oncology, Regulatory Amgen, XGEVA, denosumab, Multiple Myeloma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news